Cancer-associated macrophage-like cells as prognostic indicators of overall survival in a variety of solid malignancies.

Daniel L. Adams(Creatv MicroTech (United States)), R. Katherine Alpaugh(Fox Chase Cancer Center), Cha‐Mei Tang(Creatv MicroTech (United States)), Jeffrey R. Marks(Duke Medical Center), Massimo Cristofanilli(Cornell University), Susan Tsai(The Ohio State University Wexner Medical Center), Diane K. Adams(Rutgers, The State University of New Jersey), Saranya Chumsri(Jacksonville College), Raymond C. Bergan(University of Nebraska Medical Center), Thai H. Ho(Mayo Clinic in Arizona), Rena G. Lapidus(University of Maryland, Baltimore), Stuart S. Martin(University of Maryland, Baltimore), Steven H. Lin(The University of Texas MD Anderson Cancer Center)
Journal of Clinical Oncology
May 20, 2017
10.1200/jco.2017.35.15_suppl.11503
Cited by 15

Related Papers

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
|The Lancet Oncology|2016|1.8k
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
|New England Journal of Medicine|2015|1.6k
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
|New England Journal of Medicine|2018|1.3k
Integrating genomic features for non-invasive early lung cancer detection
|Nature|2020|689
Neuropeptide S
|Neuron|2004|516